Literature DB >> 23428925

Successful conversion from thiazide to tolvaptan in a patient with stage d heart failure and chronic kidney disease before heart transplantation.

Teruhiko Imamura1, Koichiro Kinugawa, Naoko Kato, Shun Minatsuki, Hironori Muraoka, Toshiro Inaba, Hisataka Maki, Taro Shiga, Masaru Hatano, Atsushi Yao, Shunei Kyo, Minoru Ono, Issei Komuro.   

Abstract

Chronic kidney disease (CKD) is often complicated with advanced heart failure because of not only renal congestion and decreased renal perfusion but also prolonged use of diuretics at higher doses, which sometimes results in hyponatremia. Preoperative CKD is known to be associated with poor prognosis after heart transplantation (HTx). We experienced a stage D heart failure patient with CKD and hyponatremia who was switched from trichlormethiazide to tolvaptan. His hyponatremia was normalized, and his renal function was improved after conversion to tolvaptan. In patients with stage D heart failure, it may be useful to administer tolvaptan with a concomitant reduction in the dose of diuretics in order to preserve renal function and avoid hyponatremia before HTx.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23428925     DOI: 10.1536/ihj.54.48

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


  2 in total

Review 1.  Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure.

Authors:  Teruhiko Imamura; Koichiro Kinugawa
Journal:  Int J Mol Sci       Date:  2016-01-14       Impact factor: 5.923

2.  Long-term effects of tolvaptan in patients requiring recurrent hospitalization for heart failure.

Authors:  Hayato Ogawa; Masayoshi Ajioka; Hideki Ishii; Takahiro Okumura; Yosuke Murase; Hiroyuki Osanai; Yoshihito Nakasima; Hiroshi Asano; Kazuyoshi Sakai; Toyoaki Murohara
Journal:  Nagoya J Med Sci       Date:  2015-08       Impact factor: 1.131

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.